Keybanc initiated coverage of Codex DNA with a rating of Overweight and set a new price target of $30.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2022 | Outperform | Cowen | |
| 10/15/2021 | Outperform | Cowen | |
| 7/13/2021 | $23.00 | Buy | Jefferies |
| 7/13/2021 | Outperform | Cowen & Co. | |
| 7/13/2021 | $30.00 | Overweight | Keybanc |
4 - Telesis Bio Inc. (0001850079) (Issuer)
3 - Telesis Bio Inc. (0001850079) (Issuer)
4 - Telesis Bio Inc. (0001850079) (Issuer)
Cowen resumed coverage of Codex DNA with a rating of Outperform
Cowen resumed coverage of Codex DNA with a rating of Outperform
Jefferies initiated coverage of Codex DNA with a rating of Buy and set a new price target of $23.00
SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13D - Telesis Bio Inc. (0001850079) (Subject)
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer leveraging Telesis Bio's SOLA platform for enzymatic DNA synthesis technology SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today pre-announced certain preliminary, unaudited financial results for the fourth quarter ended December 31, 2022. The results are subject to the completion of the Company's year-end financial reporting processes, reviews, and audit. Telesis Bio also announced that it has a
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve
8-K - Telesis Bio Inc. (0001850079) (Filer)
10-Q - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. Recent HighlightsContinued execution across all areas of the growth strategy: Increased total revenue by 98% over prior year periodGrew revenue by 44% on an organic basis year over year, excluding contributions from Eton Bioscience acquisitionDelivered solid growth in BioXp 3250 instrument placementsExperienced record high BioXp kit revenues, driven by growth in gene fragments, cloning, and DNA library kitsLaunched MyBioXperience, a new e-commerce solution, which dramatically sim